These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23582562)

  • 1. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review.
    Souza SJ; Luzia LA; Santos SS; Rondó PH
    Rev Assoc Med Bras (1992); 2013; 59(2):186-98. PubMed ID: 23582562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
    Sension M; Deckx H
    AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.
    Liu E; Armstrong C; Spiegelman D; Chalamilla G; Njelekela M; Hawkins C; Hertzmark E; Li N; Aris E; Muhihi A; Semu H; Fawzi W
    Clin Infect Dis; 2013 Jun; 56(12):1820-8. PubMed ID: 23449270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI.
    Liu S; Wei B; Liang W; Chen T; Deng L; Zhao M; Wan J
    Front Public Health; 2023; 11():1161503. PubMed ID: 37181701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching strategies to improve lipid profile and morphologic changes.
    Barragan P; Fisac C; Podzamczer D
    AIDS Rev; 2006; 8(4):191-203. PubMed ID: 17219734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy.
    Bergersen BM
    Drugs; 2006; 66(15):1971-87. PubMed ID: 17100407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma lipid profile in pregnant women with HIV receiving nevirapine.
    Floridia M; Tamburrini E; Anzidei G; Tibaldi C; Guaraldi G; Guerra B; Meloni AM; Vimercati A; Molinari A; Pinnetti C; Dalzero S; Ravizza M;
    AIDS Patient Care STDS; 2009 Mar; 23(3):147-52. PubMed ID: 19866532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
    Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
    AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid metabolism in treated HIV Infection.
    Dubé MP; Cadden JJ
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
    Bwakura-Dangarembizi M; Musiime V; Szubert AJ; Prendergast AJ; Gomo ZA; Thomason MJ; Musarurwa C; Mugyenyi P; Nahirya P; Kekitiinwa A; Gibb DM; Walker AS; Nathoo K;
    Pediatr Infect Dis J; 2015 Feb; 34(2):e23-31. PubMed ID: 25068287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
    Nolan D
    Drug Saf; 2005; 28(12):1069-74. PubMed ID: 16329710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
    Fontas E; van Leth F; Sabin CA; Friis-Møller N; Rickenbach M; d'Arminio Monforte A; Kirk O; Dupon M; Morfeldt L; Mateu S; Petoumenos K; El-Sadr W; de Wit S; Lundgren JD; Pradier C; Reiss P;
    J Infect Dis; 2004 Mar; 189(6):1056-74. PubMed ID: 14999610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study.
    Kamara DA; Smith C; Ryom L; Reiss P; Rickenbach M; Phillips A; Mocroft A; De Wit S; Law M; Monforte AD; Dabis F; Pradier C; Lundgren JD; Sabin C
    Antivir Ther; 2016; 21(6):495-506. PubMed ID: 27114439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
    Rokx C; Verbon A; Rijnders BJ
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)].
    ;
    Enferm Infecc Microbiol Clin; 2014; 32(7):446.e1-42. PubMed ID: 24953253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.